Industry Updates for the Psychedelics World

Psychedelics News

Industry

10 Jun 2022

A Look at Small Pharma’s Year-End Highlights

With a unique DMT trial currently in Phase 2a for major depressive disorder Small Pharma is a company worth keeping an eye on....

By Jason Najum

Industry

7 Jun 2022

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Today we received news that Cybin is continuing to aggressively pursue its DMT development with the acquisition of a major DMT study from Entheon Biomedical...

By Microdose NewsDesk

Industry

3 Jun 2022

The Top Clinical Trials in 2022

2022 is expected to be a pivotal year, with the psychedelic industry attempting to solidify itself as a commercially viable endeavor....

By Jason Najum

Industry

31 May 2022

Cybin Submits IND to FDA for Phase 1/2a Trial of CYB003

Cybin moved their pipeline forward, submitting an IND to the FDA for a Phase 1/2a clinical trial for CYB-003...

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

25 May 2022

Microdose Helps Bring Psychedelic Medicine to Davos

Microdose was there, to speak and be part of this leadership group bringing psychedelic medicine to a broader audience, one that could help move the industry forward....

By Microdose NewsDesk

Don’t Miss, Industry

24 May 2022

News You Might Have Missed: May 24th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

23 May 2022

COMPASS Presents Psilocybin Study to American Psychiatric Association

Positive data from phase IIb study shows potential of COMP360 psilocybin therapyin treatment-resistant depression...

By Microdose NewsDesk

Industry

20 May 2022

Awakn Life Sciences Completes New Study for Addiction

Awakn Life Science has announced positive results from a new study that uses ketamine for a range of addiction disorders....

By Jason Najum

Industry

19 May 2022

A Deeper Look at Affordability, Insurance, and Access

One of the biggest concerns in the psychedelic industry is affordability....

By Ritika Dubey

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result